ARTICLE | Company News
ValiRx, Cancer Research UK deal
August 23, 2010 7:00 AM UTC
ValiRx exercised an option to license exclusive, worldwide rights to Cancer Research's VAL 201 to diagnose, treat and prevent cancer and other diseases. VAL 201 is a Src kinase inhibitor peptide in p...